Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Brian Savage reports proposed sales of Teva ordinary shares and an upcoming RSU vesting. The filing lists three dispositions: 450 shares on 01/30/2026 for $15,178.95, 1,000 shares on 12/12/2025 for $29,910.70, and 1,274 shares on 03/03/2026 for $41,226.51.
The notice also shows 3,580 restricted share units vesting on 03/05/2026 described as a compensation award.
Brian Savage reports proposed sales of Teva ordinary shares and an upcoming RSU vesting. The filing lists three dispositions: 450 shares on 01/30/2026 for $15,178.95, 1,000 shares on 12/12/2025 for $29,910.70, and 1,274 shares on 03/03/2026 for $41,226.51.
The notice also shows 3,580 restricted share units vesting on 03/05/2026 described as a compensation award.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity. The filing lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026 through Citigroup Global Markets Inc. It also reports 9,908 ordinary shares sold on 03/04/2026 for $321,658.26.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity. The filing lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026 through Citigroup Global Markets Inc. It also reports 9,908 ordinary shares sold on 03/04/2026 for $321,658.26.
Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.
The filing also shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026 reported as compensation.
Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.
The filing also shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026 reported as compensation.
Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes. The filing lists two transactions: 80,762 ordinary shares sold on 03/03/2026 for $2,613,450.24 and 11,277 ordinary shares sold on 03/04/2026 for $366,102.17. The filing also references 19,654 restricted share units vesting on 03/05/2026.
Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes. The filing lists two transactions: 80,762 ordinary shares sold on 03/03/2026 for $2,613,450.24 and 11,277 ordinary shares sold on 03/04/2026 for $366,102.17. The filing also references 19,654 restricted share units vesting on 03/05/2026.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.). The filing lists Richard Daniell as the selling person and shows earlier dispositions in the prior three months: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026, with corresponding gross proceeds included in the excerpt.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.). The filing lists Richard Daniell as the selling person and shows earlier dispositions in the prior three months: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026, with corresponding gross proceeds included in the excerpt.
TEVA Pharmaceutical Industries Chief Accounting Officer Amir Weiss exercised 5,179 Restricted Share Units on March 3, 2026, converting them into 5,179 Ordinary Shares at a reported price of $0.0000 per share. Following the conversion, he held 10,829 Ordinary Shares directly and 5,180 restricted share units remain scheduled to vest on March 3, 2027. The restricted share units were originally granted on March 3, 2023, with 5,179 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA Pharmaceutical Industries Chief Accounting Officer Amir Weiss exercised 5,179 Restricted Share Units on March 3, 2026, converting them into 5,179 Ordinary Shares at a reported price of $0.0000 per share. Following the conversion, he held 10,829 Ordinary Shares directly and 5,180 restricted share units remain scheduled to vest on March 3, 2027. The restricted share units were originally granted on March 3, 2023, with 5,179 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.
He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.
He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.
Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.
Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.
Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.
Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.
Teva Pharmaceutical Industries Ltd reported insider transactions by President and CEO Francis Richard on March 3, 2026. He exercised restricted share units into ordinary shares and then sold a portion of the resulting holdings.
The filing shows exercises or conversions of restricted share units into 67,231 and 891,315 ordinary shares at a stated price of $0.0000 per share, and open-market sales totaling 442,935 ordinary shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. The transactions were effected under a Rule 10b5-1 trading plan, and some shares were sold to cover tax withholding obligations related to vesting restricted share units.
After these transactions, Richard directly held 1,121,382 ordinary shares. Footnotes explain that restricted share units were originally granted or earned based on performance and time-based vesting criteria and that each unit represents a right to receive one ordinary share or its cash value.
Teva Pharmaceutical Industries Ltd reported insider transactions by President and CEO Francis Richard on March 3, 2026. He exercised restricted share units into ordinary shares and then sold a portion of the resulting holdings.
The filing shows exercises or conversions of restricted share units into 67,231 and 891,315 ordinary shares at a stated price of $0.0000 per share, and open-market sales totaling 442,935 ordinary shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. The transactions were effected under a Rule 10b5-1 trading plan, and some shares were sold to cover tax withholding obligations related to vesting restricted share units.
After these transactions, Richard directly held 1,121,382 ordinary shares. Footnotes explain that restricted share units were originally granted or earned based on performance and time-based vesting criteria and that each unit represents a right to receive one ordinary share or its cash value.